Insilico Medicine
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Insilico Medicine Reports Positive Phase IIa Results for ISM001-055, a Novel First-in-Class Drug Treatment for Idiopathic Pulmonary Fibrosis (IPF) Designed Using Generative AI 2024-09-18 21:30
AI for Good: Insilico Medicine Hosts IMGAIA Product Launch Event 2024-07-24 21:00
1